U.S. Markets closed

Lyra Therapeutics, Inc. (LYRA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.10+0.06 (+0.75%)
At close: 4:00PM EDT

8.10 0.00 (0.00%)
After hours: 4:00PM EDT

Lyra Therapeutics, Inc.

480 Arsenal Way
Watertown, MA 02472
United States
617 393 4600
http://www.lyratherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees38

Key Executives

NameTitlePayExercisedYear Born
Dr. Maria Palasis Ph.D.Chair of the Board, CEO & Pres754.07kN/A1965
Mr. R. Donald ElseyCFO, Treasurer & Sec.536.34kN/A1954
Dr. Robert Richard Ph.D.Sr. VP of R&D366.74kN/A1957
Dr. Carmichael S. Roberts Jr.Co-FounderN/AN/A1969
Mr. Ray KnoxVP of OperationsN/AN/AN/A
Ms. Corinne NoyesSr. VP of Commercial Strategy & Market Devel.N/AN/A1968
Ms. Vineeta Belanger Ph.D.Sr. VP of Clinical AffairsN/AN/AN/A
Ms. Pamela E. NelsonSr. VP of Regulatory AffairsN/AN/A1970
Dr. Robert Kern M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Lyra Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.